News for Editas Medicine, Inc. (EDIT)

Editas Medicine (EDIT) shares gained amidst FDA Center changes, reflecting resilience in the biotech sector. Analysts foresee a potential 43.62% upside

Editas Medicine (EDIT) has decided to prioritize its in vivo liver-directed prime editing initiatives, particularly targeting Wilson's disease and alpha-1 antit

Editas Medicine, Inc. (NASDAQ:EDIT) BofA Securities 2025 Healthcare Conference May 14, 2025 8:15 PM ETCompany ParticipantsAmy Parison - CFOChristi Bernett -...

Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using

Editas Medicine (EDIT) recently unveiled promising in vivo data showcasing significant editing of the HBG1/2 promoter in hematopoietic stem cells (HSCs), utiliz

As of March 31, 2025, Editas Medicine (EDIT) had cash, cash equivalents, and marketable securities totaling $221.0 million. This is a decrease from the $269.9 m

Editas Medicine (EDIT) reported a substantial increase in revenue for the first quarter, reaching $4.658 million. This result significantly surpassed analysts'

Editas Medicine Inc (EDIT) sees a remarkable surge in Q1 revenue, up 308.8% year-over-year. Current analyst consensus rates Editas Medicine as a "Hold"

Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoi

CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. ( EDIT), a pioneering gene editing company, today announced that the U.S. Court of Ap

Key Highlights: Editas Medicine (EDIT) gears up for its Q1 earnings release, with analysts forecasting a notable EPS increase. Wall Street projects a sig

Editas Medicine (EDIT) Q1 earnings reveal on May 12: EPS est. at -$0.59 (up 22.4% Y/Y), revenue est. $0.71M (down 37.7% Y/Y).

PR NewswireAUSTIN, Texas, May 8, 2025 Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna SethAUSTIN, Texas, May 8, 2025 /P

Editas Medicine struggles with underwhelming data and lacks major partnerships. Find out why EDIT stock faces significant risks with little catalyst until 2026.

**media[582597]**

Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025

**media[572477,572478]**

**media[572461,572462]**

Editas Medicine, Inc. (NASDAQ:EDIT) Barclays 27th Annual Global Healthcare Conference March 11, 2025 9:00 AM ETCompany ParticipantsGilmore O’Neill -...